On August 8, 2024, Novavax, Inc., a biotechnology company incorporated in Delaware and headquartered in Gaithersburg, Maryland, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This registration statement pertains to the issuance of additional shares under the company's employee benefit plans. Specifically, Novavax registered 1,810,264 additional shares of common stock for its Amended and Restated 2013 Employee Stock Purchase Plan and 6,500,000 additional shares for its Amended and Restated 2015 Stock Incentive Plan. The filing includes references to previous registration statements and incorporates by reference several of Novavax's financial documents, including annual and quarterly reports, as well as current reports and proxy statements. The registration statement also details the company's indemnification policies for directors and officers, and includes a list of exhibits related to the company's corporate governance documents.

On August 8, 2024, Novavax, Inc., a biotechnology company incorporated in Delaware and headquartered in Gaithersburg, Maryland, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This registration statement pertains to the issuance of additional shares under the company's employee benefit plans. Specifically, Novavax registered 1,810,264 additional shares of common stock for its Amended and Restated 2013 Employee Stock Purchase Plan and 6,500,000 additional shares for its Amended and Restated 2015 Stock Incentive Plan. The filing includes references to previous registration statements and incorporates by reference several of Novavax's financial documents, including annual and quarterly reports, as well as current reports and proxy statements. The registration statement also details the company's indemnification policies for directors and officers, and includes a list of exhibits related to the company's corporate governance documents.